Event

Klaus F. Rabe

Pulmonary Medicine
LungClinic Grosshansdorf;LungenClinic Grosshansdorf;LungenClinic Grosshansdorf and Christian Albrechts University;LungenClinic Grosshansdorf and Christian-Albrechts University, Kiel, Airway Research C

MeiLan K. Han

MD, MS
Univ Michigan Hlth Care System;University of Michigan;University of Michigan Health System;University of Michigan School of Medicine;University of Michigan, Ann Arbor

Alberto de la Hoz

MD
Boehringer Ingelheim Pharma GmbH & Co. KG

Fernando J. Martinez

MD, MS
Cornell University;New York-Presbyterian Hospital/Weill Cornell Medical Center;Weill Cornell Medical College;Weill Cornell Medical College, Cornell University;Weill Cornell Medicine

Marc Miravitlles

MD, PhD
Hospital Universitari Vall d'Hebron;Hospital Universitari Vall d'Hebron, CIBER de Enfermedades Respiratorias (CibeRes);Hospital Vall d'Hebron

Dave Singh

MD, NP
Manchester Academic Health Science Centre, The University of Manchester;Medicines Evaluation Unit (MEU), University of South Manchester NHS Foundation Trust;The University of Manchester, University Ho

Florian Voss

-
Boehringer Ingelheim Pharma GmbH & Co. KG

David M. G. Halpin

PhD
Royal Devon and Exeter Hospital;Royal Devon and Exeter Hospital, University of Exeter Medical School

A Composite Endpoint of Clinically Important Deterioration in Chronic Obstructive Pulmonary Disease and Its Association with Increased Mortality: A Post Hoc Analysis of the UPLIFT Study